NVONew data, same message: Wegovy still hits
Novo Nordisk is back at the European Congress on Obesity with more evidence that Wegovy isn’t just a one-hit wonder. In a new STEP UP sub-analysis, people who were early responders — meaning they’d already lost at least 15% of their weight after 24 weeks — went on to lose an average of 27.7% by week 72 on the higher 7.2 mg dose.
That’s not exactly “I skipped the gym once” progress. It’s the kind of number that keeps the obesity-drug race looking very much like Novo vs. everyone else, with investors glued to every fresh data drop like it’s the next season finale.
Faster progress, fatter upside
The company also said the higher dose helped patients hit weight-loss goals faster than semaglutide 2.4 mg. And in the body-composition analysis, Novo said 84% of the weight loss from Wegovy came from fat mass, while muscle function was preserved.
That matters because the obesity market isn’t just about watching the scale move. It’s about whether the drug can deliver meaningful weight loss without making patients feel like they melted into a puddle of lean tissue.
Why investors should care
For Novo, this is another confidence-builder around the Wegovy franchise just days after the company has been in the headlines for other pipeline and outlook updates. The broader takeaway: the obesity story is still evolving, and Novo keeps trying to widen the moat with better dosing, better data, and a whole lot of clinical trial math.
Big picture: if you own NVO, this is the kind of update that doesn’t rewrite the thesis — it reinforces it. And in pharma, boring consistency can be very profitable.